Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2024

Open Access 08-05-2024 | Brentuximab vedotin | short review

Antibody–drug conjugates in the treatment of lymphoid neoplasms

Authors: Univ. Prof. Dr. Peter Neumeister, PD Dr. med. univ. et scient. med. Katharina Theresa Prochazka

Published in: memo - Magazine of European Medical Oncology | Issue 2/2024

Login to get access

Summary

Antibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a cytotoxic drug directly to the target cell thereby minimising side effects and improving the therapeutic index. In recent years, many new ADCs have been approved and are established therapeutic tools in lymphoma treatment.
Literature
1.
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma.ECHELON‑1 Study Group. N Engl J Med. 2022;28;387(4):310–20. Jul.CrossRef
2.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;20;132(25:2639–42.CrossRef
3.
Rutherford SC, Hongli L, Herrera AF, et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. Presented at ASH 2023. December. San Diego, CA Abstract. 2023;181:9–12.
4.
Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;.
5.
Borchmann P, Moccia A, Grell R, et al. Treatment related morbidity in patients with classical hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by the German Hodgkin Study Group. Blood. 2022;140((suppl 1):771–3.CrossRef
6.
7.
8.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. J Clin Oncol. 2022
9.
LaCasce AS, et al. Brentuximab. a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood: vedotin plus bendamustine; 2018. Vol 132, Number 1.
10.
Ranjana H. Advani. et al., Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3‑year study results. Blood, 2021 Vol 138, NUMBER 6.
11.
Massaro F, et al. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis. Cancers. 2022;14:982.CrossRefPubMedPubMedCentral
12.
Horwitz s. et al. The ECHELON‑2 Trial. 5‑year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T‑cell lymphomaAnnals of Oncology. Volume. 2022;33(3):288–98.
13.
Barbara Pro, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. BLOOD, 21; 2017, Vol 130, Number 25.
14.
Carmelo Carlo-Stella, et al. Camidanlumab Tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical hodgkin lymphoma (R/R CHL). EHA. 2022;201.
15.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B‑Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155–165. https://​doi.​org/​10.​1200/​JCO.​19.​00172.
16.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B‑Cell Lymphoma. N Engl J Med. 2021;14.
17.
Hutchings M, et al. Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B‑cell lymphoma. ICML. 2023.CrossRef
18.
Adam J Olszewski, et al. Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged < 65 and ≥ 65 years with relapsed/refractory DLBCL and ≥ 1 prior therapy: subgroup analysis of a Phase Ib/II study. Poster Presentation at the 64th ASH Annual Meeting P1630.
19.
Jason Westin, et al. SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin versus Rituximab in Combination with Gemcitabine plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B‑cell Non-Hodgkin Lymphoma. Poster Presentation at the 64th ASH Annual Meeting P1637.
20.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B‑cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. Jun.CrossRefPubMed
21.
Caimi PF, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B‑cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 2023;31.
22.
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O’Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.CrossRefPubMedPubMedCentral
23.
Kantarjian HM, et al. Inotuzumab Ozogamicin Versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long-Term Survival Follow-Up From the Randomized, Phase 3 INO-VATE Study. Cancer. 2019;125:2474–87.CrossRefPubMed
24.
Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gokbuget N, Advani AS, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905–13.CrossRefPubMed
25.
Dimopoulos MA, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801–e812.
26.
Kreitman RJ, et al. Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. Blood. 2019;134(Suppl. 1 Nov 13).
Metadata
Title
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Authors
Univ. Prof. Dr. Peter Neumeister
PD Dr. med. univ. et scient. med. Katharina Theresa Prochazka
Publication date
08-05-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2024
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00965-x

Other articles of this Issue 2/2024

memo - Magazine of European Medical Oncology 2/2024 Go to the issue

editorial

Rare lung cancer special: a multifaceted approach

short review

Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents

short review

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

review

The future of clinical trials—goals, ideas, and discussion

short review

Antibody–drug conjugates in ovarian cancer

editorial

Congress update 2023—ASCO and ESMO
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits